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demethylation of the brain-derived neuro-
trophic factor (Bdnf) and fibroblast growth 
factor 1 (Fgf1) gene promoters as part of a 
physiological response to electroconvulsive 
stimulation23. One seemingly inconsistent  
example is that of myeloid tumours  
carrying TET2 mutations that decrease 
its activity, where decreased global 5hmC 
levels are actually associated with CpG 
hypomethylation, but it is possible that the 
methylation machinery is also impaired in 
these tumours10. Finally, loss of 5mC from 
the paternal genome in the fertilized egg 
correlates with an increase in 5hmC in the 
male pronucleus at a time when the female 
pronucleus remains methylated and contains 
low levels of 5hmC18–20. This striking asym-
metry is highly suggestive of an involvement 
of 5hmC in demethylation of the paternal 
genome, and indeed TET3-depleted zygotes 
fail to demethylate the male pronucleus18,20 
and, in particular, certain promoter regions 
(for example, Oct4 (also known as Pou5f1) 
and Nanog)18. This is compelling evidence 
that TET3 is involved in DNA demethyla-
tion, potentially through oxidation of 5mC. 
Nonetheless, a direct link to the catalytic 
activity of the enzyme is still missing, and 
it is possible that there is a non-catalytic 
function of TET3 in demethylation. More 
recently, it was shown by immunostaining 
that paternal 5hmC is lost passively through 
replication during pre-implantation develop-
ment29, suggesting that 5mC is converted 
to 5hmC, which is then removed through 
replication. Because immunostaining is not 
quantitative, it remains possible that only a 
portion of 5mC is converted to 5hmC, and 
the remaining 5mC is removed by a distinct 
pathway. Indeed, demethylation of trans-
posable elements is apparent by bisulphite 
sequencing before replication is initiated30.
Potential mechanisms. Conversion of 5mC 
to 5hmC could promote passive demethyla-
tion at the time of replication by preventing 
DNMT1 activity at hydroxymethylated 
CpGs. But, whereas DNMT1 is not active at 
hemi-hydroxymethylated CpGs31 in vitro, 
the chaperone UHRF1 (which is also known 
as NP95 and is crucial for DNMT1 func-
tion) binds both 5mC and 5hmC with 
similar affinities32, potentially promoting 
DNMT1 activity at hydroxymethylated 
CpGs. Current in vivo evidence from pre-
implantation embryos suggests that 5hmC 
is passively removed through replication29, 
but further studies are required to clarify 
this point.
In terms of potential active demethylation 
pathways, 5hmC may be removed through a 
deamination pathway that is similar to that 
discussed above, in which AID/APOBEC 
deaminases act on 5mC (FIG. 1). Indeed, over-
expression of AID/APOBEC deaminases in 
neural cells promotes the removal of 5hmC, 
and both TET1 and AID overexpression lead 
to a global accumulation of 5-hydroxymeth-
yluracil (5hmU), the deamination product 
of 5hmC23. Furthermore, both single-strand-
selective monofunctional uracil-DNA 
glycosylase 1 (SMUG1) and TDG glycosy-
lases have strong activity towards 5hmU:G 
mismatches and appear to be involved in 
this pathway23,33. The potential redundan-
cies between the multiple deaminase and 
glycosylase activities that operate in vivo are 
likely to complicate future studies of such 
mechanisms.
Another active pathway that has been 
proposed involves further oxidation steps 
that would modify 5hmC first to 5fC and 
then to 5caC (FIG. 1). Indeed, all three TETs 
were recently shown to catalyse these addi-
tional oxidation steps, and both 5fC and 
5caC were detected in ESCs, albeit at very 
low levels22,24,25. Reduced preference of TETs 
towards 5hmC as a substrate (in comparison 
to 5mC)25 and/or fast removal of 5fC and 
5caC could explain their low abundance. 
Interestingly, TDG can remove both 5fC and 
5caC24,34, raising the suggestion that the BER 
machinery might operate in this pathway as 
well. However, it is possible that activities 
that deformylate 5fC or decarboxylate 5caC 
(generating C) also exist.
It is likely that there are multiple  
pathways for the removal of 5mC from the 
genome and that TET enzymes are involved 
in several of them. One interesting possibil-
ity is that different tissues might use dif-
ferent demethylation pathways, depending 
on whether demethylation is genome-wide 
or local and on its targets in the genome, 
for example.
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Chapter 1  Introduction to the EpiTYPER® Assay2
EpiTYPER® Application Guide
For Research Use Only. Not for Use in Diagnostic Procedures.
UG11570 R2.0 CO 110074
March 25, 2011
 




The process of base-specific cleavage generates products that can be analyzed to illustrate 
a complete picture of DNA methylation, including:
• the detection of differentially methylated genes, 
• the analysis of methylation patterns, and 
• the semi-quantitative determination of differences in the degree of methylation.
Two base-specific cleavage reactions (T reverse and C reverse) are performed to discover 
methylation sites and to determine methylation ratios within a given target region. Up to 
85% of the CpGs within a target region are represented in the two cleavage reactions 
depending on the sequence content and the distribution of CpG sites.
EpiTYPER® Assay for 
Quantitative 
Methylation Analysis
The EPITYPER® samples are processed using the T-cleavage reverse and C-cleavage 
reverse reactions from the homogeneous MassCLEAVETM (hMC) reaction before being 
run in the mass spectrometer.
Figure 1.1   Overview of EpiTYPER® Assay
Uracil-specific cleavage
MALDI-TOF MS analysis 
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Well( Total(modified(C(%( mC(%( hmC(%( C(%(
1( 0.0( 0.0( 0.0( 100.0(
2( 23.5( 23.2( 0.3( 76.5(
3( 30.0( 29.5( 0.5( 70.0(
4( 50.0( 48.9( 1.1( 50.0(
5( 60.0( 57.9( 2.1( 40.0(
6( 70.0( 65.8( 4.3( 30.0(
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demethylation of the brain-derived neuro-
trophic factor (Bdnf) and fibroblast growth 
factor 1 (Fgf1) gene promoters as part of a 
physiological response to electroconvulsive 
stimulation23. One seemingly inconsistent  
example is that of myeloid tumours  
carrying TET2 mutations that decrease 
its activity, where decreased global 5hmC 
levels are actually associated with CpG 
hypomethylation, but it is possible that the 
methylation machinery is also impaired in 
these tumours10. Finally, loss of 5mC from 
the paternal genome in the fertilized egg 
correlates with an increase in 5hmC in the 
male pronucleus at a time when the female 
pronucleus remains methylated and contains 
low levels of 5hmC18–20. This striking asym-
metry is highly suggestive of an involvement 
of 5hmC in demethylation of the paternal 
genome, and indeed TET3-depleted zygotes 
fail to demethylate the male pronucleus18,20 
and, in particular, certain promoter regions 
(for example, Oct4 (also known as Pou5f1) 
and Nanog)18. This is compelling evidence 
that TET3 is involved in DNA demethyla-
tion, potentially through oxidation of 5mC. 
Nonetheless, a direct link to the catalytic 
activity of the enzyme is still missing, and 
it is possible that there is a non-catalytic 
function of TET3 in demethylation. More 
recently, it was shown by immunostaining 
that paternal 5hmC is lost passively through 
replication duri g pre-implantation develop-
ment29, suggesting that 5mC is converted 
to 5hmC, which is then removed through 
replication. Because immunostaining is not 
quantitative, it remains possible that only a 
portion of 5mC is converted to 5hmC, and 
the remaining 5mC is removed by a distinct 
pathway. Indeed, demethylation of trans-
posable elements is apparent by bisulphite 
sequencing before replication is initiated30.
Potential mechanisms. Conversion of 5mC 
to 5hmC could promote passive demethyla-
tion at the time of replication by preventing 
DNMT1 activity at hydroxymethylated 
CpGs. But, whereas DNMT1 is not active at 
hemi-hydroxymethylated CpGs31 in vitro, 
the chaperone UHRF1 (which is also known 
as NP95 and is crucial for DNMT1 func-
tion) binds both 5mC and 5hmC with 
similar affinities32, potentially promoting 
DNMT1 activity at hydroxymethylated 
CpGs. Current in vivo evidence from pre-
implantation embryos suggests that 5hmC 
is passively removed through replication29, 
but further studies are required to clarify 
this point.
In terms of potential active demethylation 
pathways, 5hmC may be removed through a 
deamination pathway that is similar to that 
discussed above, in which AID/APOBEC 
deaminases act on 5mC (FIG. 1). Indeed, over-
expression of AID/APOBEC deaminases in 
neural cells promotes the removal of 5hmC, 
and both TET1 and AID overexpression lead 
to a global accumulation of 5-hydroxymeth-
yluracil (5hmU), the deamination product 
of 5hmC23. Furthermore, both single-strand-
selective monofunctional uracil-DNA 
glycosylase 1 (SMUG1) and TDG glycosy-
lases have strong activity towards 5hmU:G 
mismatches and appear to be involved in 
this pathway23,33. The potential redundan-
cies between the multiple deaminase and 
glycosylase activities that operate in vivo are 
likely to complicate future studies of such 
mechanisms.
Another active pathway that has been 
proposed involves further oxidation steps 
that would modify 5hmC first to 5fC and 
then to 5caC (FIG. 1). Indeed, all three TETs 
were recently shown to catalyse these addi-
tional oxidation steps, and both 5fC and 
5caC were detected in ESCs, albeit at very 
low levels22,24,25. Reduced preference of TETs 
towards 5hmC as a substrate (in comparison 
to 5mC)25 and/or fast removal of 5fC and 
5caC could explain their low abundance. 
Interestingly, TDG can remove both 5fC and 
5caC24,34, raising the suggestion that the BER 
machinery might operate in this pathway as 
well. However, it is possible that activities 
that deformylate 5fC or decarboxylate 5caC 
(generating C) also exist.
It is likely that there are multiple  
pathways for the removal of 5mC from the 
genome and that TET enzymes are involved 
in several of them. One interesting possibil-
ity is that different tissues might use dif-
ferent demethylation pathways, depending 
on whether demethylation is genome-wide 
or local and on its targets in the genome, 
for example.
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DNMT1 activity at hydroxymethylated 
CpGs. Current in vivo e id nce from pre-
implantation embryos suggests that 5hmC 
is pa sively r moved through replication29, 
but furthe  studies are required to clarify 
this point.
In terms of p tential active demethylation 
pathways, 5hmC ay be removed through a 
deamination pathway that is similar to that 
discus ed above, in which AID/APOBE  
deaminases act on 5mC (FIG. 1). Indeed, over-
expr ssion of AID/APOBEC deaminases in 
neural cel s promotes the removal of 5hmC, 
and both TET1 and AID overexp ssion lead 
to a globa  accumulation of 5-hydroxymeth-
yluracil (5hmU), the deamination product 
of 5hmC23. Furthe mo e, both single-strand-
selective monofunctional uracil-DNA 
glycos la e 1 (SMUG1) and TDG glycos -
lases have strong activity towards 5hmU:G 
mis atches and ppear to be involved in 
this pathway23,33. The potential redun a -
cies b tween the multiple deaminase and
glycos la e activities hat operat  in vivo are 
likely to complicate future studies of uch 
mechanisms.
Another active pathway that has been 
proposed involves furthe  oxidation step  
that would modify 5hmC first to 5fC and
then to 5caC (FIG. 1). Indeed, all three TETs 
were r cently shown to catalyse these addi-
tional oxidation step , and both 5fC and
5caC were detected in ESCs, albeit at very 
low evels22,24,25. Reduced preference of TETs 
towards 5hmC as a substrate (in comparison 
to 5mC)25 and/or fast removal of 5fC and
5caC ould explain their low abundance. 
Interestingly, TDG can remove both 5fC and
5caC24,34, raising the suggestion that e BER 
machinery might operate in this pathway as 
well. However, it is po sible that activities 
that deformylate 5fC or decarboxylate 5caC 
(generating C) also exist.
It is likely that t ere are multiple  
pathways for the removal of 5mC from the 
genome and that TET enzymes ar  involved 
in several of them. One int resting possibil-
ity is that different tissue  might use dif-
ferent demethylation pathways, depending 
on whether d methylation is genome-wide 
or loca  and o  its targets in the genome, 
for example.
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demethylation of the brain-derived neuro-
trophic f ctor (Bdnf) and fibroblast growth 
actor 1 (Fgf1) gene promoters as part of a 
physiological response to electroconvulsive 
sti ulation23. One seemingly inconsistent  
example is that of myeloid tumours  
c rrying TET2 mutations that decrease 
it activ t , where decreased global 5hmC 
levels ar  actually associated with CpG 
ypomethylation, but it is possible that the 
m thylati n machinery is also impaired in 
these tumo rs10. Finally, loss of 5mC from 
the pat rnal ge ome in the fertilized egg 
c rrel tes with an increase in 5hmC in the 
male pro ucleus at a time when the female 
pronucleus remains methylated and contains 
low levels of 5hmC18–20. This striking asym-
metry is highly suggestive of an involvement 
of 5hmC in demethylation of the paternal 
genome, and indeed TET3-depleted zygotes 
fail to demethylate the male pronucleus18,20 
and, in particular, certain promoter regions 
(for example, Oct4 (also known as Pou5f1) 
and Nanog)18. This is compelling evidence 
that TET3 is involved in DNA demethyla-
tion, potentially through oxidation of 5mC. 
Nonetheless, a direct link to the catalytic 
activity of the enzyme is still missing, and 
it is possible that there is a non-catalytic 
function of TET3 in demethylation. More 
recently, it was shown by immunostaining 
that paternal 5hmC is lost passively through 
replication during pre-implantation develop-
ment29, suggesting that 5mC is converted 
to 5hmC, which is then removed through 
replication. Because immunostaining is not 
quantitative, it remains possible that only a 
portion of 5mC is converted to 5hmC, and 
the remaining 5mC is removed by a distinct 
pathway. Indeed, demethylation of trans-
posable elements is apparent by bisulphite 
sequencing before replication is initiated30.
Potential mechanisms. Conversion of 5mC 
to 5hmC could promote passive demethyla-
tion at the time of replication by preventing 
DNMT1 activity at hydroxymethylated 
CpGs. But, whereas DNMT1 is not active at 
hemi-hydroxymethylated CpGs31 in vitro, 
the chaperone UHRF1 (which is also known 
as NP95 and is crucial for DNMT1 func-
tion) binds both 5mC and 5hmC with 
similar affinities32, potentially promoting 
DNMT1 activity at hydroxymethylated 
CpGs. Current in vivo evidence from pre-
implantation embryos suggests that 5hmC 
is passively removed through replication29, 
but further studies are required to clarify 
this point.
In terms of potential active demethylation 
pathways, 5hmC may be removed through a 
deamination pathway that is similar to t at 
discussed above, in which AID/APOBEC 
deaminases act on 5mC (FIG. 1). Indeed, over-
expression of AID/APOBEC deaminases in 
neural cells promotes the removal of 5hmC, 
and both TET1 and AID overexpression lead 
to a global accumulation of 5-hydroxymeth-
yluracil (5hmU), the deamination product 
of 5hmC23. Furthermore, both single-strand-
selective monofunctional uracil-DNA 
glycosylase 1 (SMUG1) and TDG glycosy-
lases have strong activity towards 5hmU:G 
mismatches and appear to be involved in 
this pathway23,33. The potential redundan-
cies between the multiple deaminase and 
glycosylase activities that operate in vivo are 
likely to complicate future studies of such 
mechanisms.
Another active pathway that has been 
proposed involves further oxidation steps 
that would modify 5hmC first to 5fC and 
then to 5caC (FIG. 1). Indeed, all three TETs 
were rec ntly shown to catalyse these addi-
tional oxidation steps, and both 5fC and 
5caC were detected in ESCs, albeit at very 
low levels22,24,25. Reduced preference of TETs 
towards 5hmC as a substrate (in comparison 
to 5mC)25 and/or fast removal of 5fC and 
5caC could explain their low abundance. 
Interestingly, TDG can remove both 5fC and 
5caC24,34, raising the suggestion that the BER 
machinery might operate in this pathway as 
well. However, it is possible that activities 
that deformylate 5fC or decarboxylate 5caC 
(generating C) also exist.
It is likely that there are multiple  
pathways for the removal of 5mC from the 
genome and that TET enzymes are involved 
in several of them. One interesting possibil-
ity is that different tissues might use dif-
ferent demethylation pathways, depending 
on whether demethylation is genome-wide 
or local and on its targets in the genome, 
for example.
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demethylation of the brain-derived neuro-
trophic factor (Bdnf) and fibroblast growth 
factor 1 (Fgf1) gene promoters as part of a 
physiological response to electroconvulsive 
stimulation23. One seemingly inconsistent  
example is that of myeloid tumours  
carrying TET2 mutations that decrease 
its activity, where decreased global 5hmC 
levels are actually associated with CpG 
hypomethylation, but it is possible that the 
methylation machinery is also impaired in 
these tumours10. Finally, loss of 5mC from 
the paternal genome in the fertilized egg 
correlates with an increase in 5hmC in the 
male pronucleus at a time when the female 
pronucleus remains methylated and contains 
low levels of 5hmC18–20. This striking asym-
metry is highly suggestive of an involvement 
of 5hmC in demethylation of the paternal 
genome, and indeed TET3-depleted zygotes 
fail to demethylate the male pronucleus18,20 
and, in particular, certain promoter regions 
(for example, Oct4 (also known as Pou5f1) 
and Nanog)18. This is compelling evidence 
that ET3 is involved in DNA demethyla-
tion, potentially through oxidation of 5mC. 
Nonetheless, a direct link to the catalytic 
activity of the enzyme is still missing, and 
it is possible that there is a non-catalytic 
function of TET3 in demethylation. More 
recently, it was shown by immunostaining 
that paternal 5hmC is lost passively thr ugh 
replicati n during pre-impla tation develop-
ment29, suggesting that 5mC is co verted 
t  5hmC, which is then removed through 
replication. Because immunostaining is not 
quantitative, it remains p ssible that only a 
portion of 5mC is converted to 5hmC, and 
the remaining 5mC is removed by a distinct 
pathway. Indeed, demethylation of trans-
pos ble lements is apparent by bisulphite 
sequencing before r lication is initiated30.
Potential mechanisms. Conversion of 5mC 
to 5hmC could promote passive demethyla-
tion at the time of r plication by preventing 
DNMT1 activity at hydroxymethylated 
CpGs. But, whereas DNMT1 is not active at 
hemi-hydroxy ethylated CpGs31 in vitro, 
the chaperone UHRF1 (which is also known 
as NP95 and is crucial for DNMT1 func-
tion) binds both 5mC a d 5hmC with 
similar affinities32, potentially promoting 
DNMT1 acti ity at hydroxymethylated 
CpGs. Current in vivo evi ence from pre-
implantation embryos suggests that 5hmC 
is passively re oved through r plic 29, 
but furt er studies are required t  clarify 
this point.
In terms of potential active demethylation 
pathways, 5hmC may be removed through a 
deamination pathway that is similar to that 
dis us ed abov , in which AID/APOBEC 
de minases act on 5mC (FIG. 1). Indeed, over-
expression of AID/APOBEC deaminases in 
neural cells promotes the removal of 5hmC, 
and both TET1 and AID overexpression lead 
to a global accumul tion of 5-hydroxymeth-
ylur cil (5hm ), the deamination product 
of 5hmC23. Fur herm re, both single-strand-
selective monofunc ional uracil-DNA 
glycosylase 1 (SMUG1) and TDG glycosy-
lases have strong activity tow rds 5hmU:G 
mismatches and appear to be in olved in 
this pathway23,33. The potential redundan-
cies between the multiple deaminase and 
glycosyl se activities that operate in vivo are 
lik ly to complica e future s udies of such 
mechanisms.
Another active pathway t at has been 
proposed involves further oxidation steps 
that would modify 5hmC first to 5fC and 
then to 5caC (FIG. 1). Indeed, all three TETs 
were recently shown to catalyse these addi-
tional oxid tion steps, and both 5fC and 
5caC were detected in ESCs, albeit at very 
low lev ls22,24,25. R duced prefere  of TETs 
towards 5hmC as a substrate (in comparison 
to 5mC)25 and/or fast removal of 5fC and 
5caC could explain their low bundance. 
Interestingly, TDG can remove both 5fC and 
5caC24,34, raising the suggestion that the BER 
m chinery might operate in this pathway as 
we l. However, it is possible that activities 
that deformylate 5fC r decarb xylat 5caC 
(g nerating C) also exist.
It is lik ly that there are multiple  
pathways for the removal of 5mC rom the 
geno e and that TET enzymes are involved 
in several of t em. O e interesting possibil-
ity is that d fferent issues might use dif-
ferent demethylation pathways, depending 
on whether demethylation is genome-wide 
or local and on its targets in the genome, 
for example.
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d methylation of the brain-derived neuro-
trophic factor (Bdnf) and fibroblast growth 
fac or 1 (Fgf1) gene promoters as part of a 
physiological response to electroconvulsive 
timulation23. One seemingly inconsistent  
example is that of myeloid tumours  
carrying TET2 mu ations th t decrease 
its activity, where ecreased global 5hmC 
evels re actually associated with CpG 
ypomethylation, but it is possible hat the 
m thylation machin ry is also impaired in 
thes tumours10. Finally, loss f 5mC from
th  pate al enome i  the fertilized egg 
correlates with an increase in 5hmC in the 
male pronucl us at  time when the female 
pr nucleus r mains methyla ed and con ains 
low lev ls of 5hmC18–20. This striking asym-
m try is highly s ggestive of an involvement 
of 5h C in dem thylation of the paternal
genome, and indeed TET3-depleted zygotes 
fail to demethylate the m le pronucleus18,20 
and, in particu r, certain promoter regions 
(for example, Oct4 (also known as Pou5f1) 
and Nanog)18. This is compelling evidence 
that TET3 is i volved in DNA demethyl -
tion, potenti lly through oxidation of 5mC. 
Non t eless, a direct link to the catalyti  
activity f the e zyme is still missing, and 
it is possible that t ere is  n n-catalytic 
function of TET3 in demethylation. More 
recently, it was shown by immunostaining 
that paternal 5hmC is lost passively through 
replication duri g pre-implantation develop-
ment29, suggesting that 5 C is converted 
to 5hmC, w ich is then removed through 
replication. Because immunostaining is not 
quantitative, it remains possible that only a 
portion of 5mC is converted to 5hmC, and 
the remaining 5mC is removed by a disti ct 
pathway. Indeed, demethylation of trans-
posable ele ents is apparent by bisulphite 
sequencing before replication is initiated30.
Potential mechanisms. Conversion of 5  
to 5hmC could promote passive demethyla-
tion at the time of replication by preventing 
DNMT1 activity at hydroxymethylated 
CpGs. But, whereas DNMT1 is not active at 
hemi-hydroxymethylated CpGs31 in vitro, 
the chaperone UHRF1 (which is also known 
as NP95 and is crucial for DNMT1 func-
tion) binds both 5 C and 5hmC with 
similar affinities32, potentially pro oting 
DNMT1 activity at hydroxymethylated 
CpGs. Current in vivo evidence from pre-
implantation embryos suggests that 5hmC 
is passively removed through replication29, 
but further studies are required to clarify 
this point.
In terms of potential active demethylation 
pathways, 5hmC may be removed through a 
deamination pathway that is similar to that 
discussed above, in which AID/APOBEC 
deaminases act on 5mC (FIG. 1). Indeed, over-
expression of AID/APOBE  deaminases in 
neural cells promotes the removal of 5hmC, 
and both TET1 and AID overexpression lead 
to a global accumulation of 5-hydroxy eth-
yluracil (5hmU), the deamination product 
of 5hmC23. Furthermore, both single-strand-
selective monofunctional uracil-DNA 
glycosylase 1 (SMUG1) and TDG glycosy-
lases have strong activity towards 5hmU:G 
mismatches and appear to be involved in 
this pathway23,33. The potential redundan-
cies between the multiple deaminase and 
glycosylase activities that operate in vivo are 
likely to complicate future studies of such 
mechanisms.
Another active pathway that has been 
proposed involves further oxidation steps 
that would modify 5hmC first to 5fC and 
then to 5caC (FIG. 1). Indeed, all three TETs 
were recently shown to catalyse these ddi-
ti n l oxidatio  teps, and both 5fC and 
5ca  were detected in ESCs, albeit at v ry 
lo  levels22,24,25. Reduced preference of TETs 
towards 5hm  s a substrate (in comparison 
t  5mC)25 and/or fast removal of 5fC and 
5caC could explain the r low a undance. 
Inter sti gly, TDG can remove both 5fC and 
5caC24,34, raising the suggestion tha  the BER 
machinery might operate in this pathway as 
well. However, it is possible that activities 
that deform l e 5fC r decarboxylate 5 aC 
(ge erati g C) als  exist.
It is lik ly hat there are mul iple  
pathways for the removal of 5mC from the 
genome an  that TET enzymes are involved 
in several of the . One interesting possibil-
ity is that diff rent tissues might use dif-
ferent de ethyl tion pathways, depending 
on whether demethylation is genome-wide 
or local and n its targets in the genome, 
for example.
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Brain(Area( Disease(status( Sex( Alu/LINE1( ELISA( GLUMA(
Visual(cortex(
AD(
Female( 26( 15( 24(
Male( 10( 5( 9(
Ctrl(
Female( 11( 8( 14(
Male( 8( 8( 12(




Female( 25( 15( 24(
Male( 10( 5( 10(
Ctrl(
Female( 12( 8( 14(
Male( 9( 8( 12(




Female( 12( 8( 11(
Male( 10( 2( 11(
Ctrl(
Female( 10( 4( 9(
Male( 8( 4( 8(




















































E S C A G C T
5
A G C T A
10











C5: G/ AC/ TG/ AC/ TG/ ACCACCA
84% 79% 78%
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Alu CA/GCA/GCA/GCCACCAC 26* 1.23 No 
LINE1 CGTGGTGCGTCG 11.8* 0.56 No 
ELISA(5mC 5mC 100 4.74 Yes 
ELISA(5hmC 5hmC 100 4.74 Yes 




































































Measure( Mean((%)( Std.(Err.! 95%(CI(
Alu( 25.88( 0.23( 25.42( 26.34(
LINE1( 74.22( 0.29( 73.65( 74.79(
ELISA(mC( 15.94( 1.52( 12.90( 18.97(
ELISA(hmC( 1.16( 0.11( 0.94( 1.37(
GLUMA(mC+hmC( 64.12( 0.79( 62.56( 65.69(
GLUMA(mC( 50.21( 1.17( 47.88( 52.55(




























































































































































































































































Female(n=( 37( 37( 23( 23( 38( 38( 38(































Female! 24.59! 73.18! 13.02! 1.05! 63.10! 46.98! 16.11!







































































































ELISA(mC(n=( 23( 15( 8( 13( 5( 8(


































































































































Variable( Coefficient( Std.(Err.( Z( p! 95%(CI(
((AD(status( O0.239( 0.204( O1.170( 0.240( O0.638( 0.160(
((Sex( O0.265( 0.184( O1.440( 0.150( O0.625( 0.095(
((Age(at(death( 0.008( 0.010( 0.800( 0.425( O0.012( 0.027(
((ApoE(genotype( 0.004( 0.017( 0.220( 0.823( O0.029( 0.037(
((Brain(area:( ((STG( O0.121( 0.177( O0.680( 0.496( O0.468( 0.226(






Variable( Coefficient( Std.(Err.( Z( p! 95%(CI(
((Braak(staging( O0.014( 0.045( O0.310( 0.759( O0.103( 0.075(
((Sex( O0.316( 0.193( O1.640( 0.101( O0.694( 0.062(
((Age(at(death( 0.006( 0.010( 0.590( 0.555( O0.014( 0.026(
((ApoE(genotype( O0.001( 0.017( O0.030( 0.974( O0.034( 0.033(
((Brain(area:( ((STG( O0.154( 0.180( O0.850( 0.393( O0.508( 0.200(




















































Variable( Coefficient( Std.(Err.( Z( p! 95%(CI(
((AD(status( 0.206( 0.804( 0.260( 0.798( O1.370( 1.782(
((Sex( 0.130( 0.659( 0.200( 0.843( O1.162( 1.422(
((Age(at(death( O0.061( 0.035( O1.750( 0.081( O0.130( 0.008(
((ApoE(genotype( O0.054( 0.064( O0.860( 0.392( O0.179( 0.070(
((Brain(area:( ((STG( O0.127( 0.361( O0.350( 0.725( O0.834( 0.581(






Variable( Coefficient( Std.(Err.( Z( p! 95%(CI(
((Braak staging( 0.031( 0.178( 0.180( 0.860( O0.318( 0.380(
((Sex( O0.220( 0.704( O0.310( 0.755( O1.599( 1.160(
((Age(at(death( O0.056( 0.036( O1.550( 0.122( O0.128( 0.015(
((ApoE(genotype( O0.058( 0.065( O0.890( 0.375( O0.186( 0.070(
((Brain(area:( ((STG( O0.193( 0.368( O0.520( 0.600( O0.915( 0.529(































































































































































































































Variable( Coefficient( Std.(Err.( Z( p! 95%(CI(
((AD(status( O0.864( 5.156( O0.170( 0.867( O10.969( 9.241(
((Sex( O3.087( 3.526( O0.880( 0.381( O9.997( 3.823(
((Age(at(death( 0.157( 0.206( 0.760( 0.445( O0.247( 0.562(
((ApoE(genotype( O0.204( 0.508( O0.400( 0.688( O1.198( 0.791(
((Brain(area:( ((STG( 1.021( 1.518( 0.670( 0.501( O1.954( 3.996(





Variable( Coefficient( Std.(Err.( Z( p! 95%(CI(
((Braak(staging( O0.262( 1.128( O0.230( 0.816( O2.474( 1.950(
((Sex( O3.801( 3.965( O0.960( 0.338( O11.572( 3.970(
((Age(at(death( 0.181( 0.216( 0.840( 0.401( O0.242( 0.604(
((ApoE(genotype( O0.181( 0.505( O0.360( 0.719( O1.170( 0.808(
((Brain(area:( ((STG( 1.209( 1.609( 0.750( 0.452( O1.944( 4.362(






Variable( Coefficient( Std.(Err.( Z( p! 95%(CI(
((AD(status( O0.265( 0.367( O0.720( 0.470( O0.984( 0.454(
((Sex( O0.171( 0.275( O0.620( 0.533( O0.709( 0.367(
((Age(at(death( 0.013( 0.015( 0.840( 0.399( O0.017( 0.042(
((ApoE(genotype( 0.032( 0.036( 0.880( 0.381( O0.039( 0.103(
((Brain(area:( ((STG( 0.107( 0.134( 0.800( 0.422( O0.155( 0.369(






Variable( Coefficient( Std.(Err.( Z( p! 95%(CI(
((Braak(staging( O0.117( 0.078( O1.510( 0.131( O0.269( 0.035(
((Sex( O0.237( 0.295( O0.800( 0.422( O0.815( 0.341(
((Age(at(death( 0.019( 0.015( 1.270( 0.205( O0.010( 0.049(
((ApoE(genotype( 0.040( 0.035( 1.140( 0.256( O0.029( 0.108(
((Brain(area:( ((STG( 0.125( 0.141( 0.880( 0.377( O0.152( 0.401(































   
   
   














































































AD! Ctrl! AD! Ctrl! AD! Ctrl!
BA9! STG! VC!
mC+hmC%! 66.9! 66.2! 65.7! 65.5! 61.5! 62.1!
!mC%! 51.7! 53.1! 49.4! 54.4! 42.6! 49.1!















































Variable( Coefficient( Std.(Err.( Z( p! 95%(CI(
((AD(status( 0.944( 1.340( 0.700( 0.481( O1.682( 3.571(
((Sex( O2.041( 1.146( O1.780( 0.075( O4.287( 0.205(
((Age(at(death( 0.054( 0.063( 0.850( 0.396( O0.070( 0.178(
((ApoE(genotype( O0.048( 0.112( O0.430( 0.668( O0.267( 0.171(
((Brain(area:( *STG( 3.677( 0.606( 6.060( <0.001( 2.488( 4.865(










Variable( Coefficient( Std.(Err.( Z( p! 95%(CI(
((Braak staging( O0.366( 0.311( O1.180( 0.239( O0.976( 0.244(
((Sex( O2.241( 1.227( O1.830( 0.068( O4.646( 0.165(
((Age(at(death( 0.103( 0.067( 1.520( 0.127( O0.029( 0.235(
((ApoE(genotype( 0.011( 0.115( 0.090( 0.927( O0.215( 0.236(
((Brain(area:( *STG( 3.750( 0.630( 5.960( <0.001( 2.517( 4.984(












Variable( Coefficient( Std.(Err.( Z( p! 95%(CI(
((AD(status( O1.487( 2.119( O0.700( 0.483( O5.640( 2.665(
*Sex( O3.971( 1.868( O2.130( 0.034( O7.633( O0.309(
((Age(at(death( O0.067( 0.097( O0.690( 0.491( O0.258( 0.124(
((ApoE(genotype( O0.091( 0.175( O0.520( 0.604( O0.433( 0.251(
((Brain(area:( *STG( 5.662( 1.196( 4.740( <0.001( 3.319( 8.005(





Variable( Coefficient( Std.(Err.( Z( p! 95%(CI(
*Braak staging( O1.059( 0.478( O2.210( 0.027( O1.995( O0.122(
*Sex( O4.934( 1.935( O2.550( 0.011( O8.726( O1.143(
((Age(at(death( 0.014( 0.101( 0.140( 0.887( O0.183( 0.211(
((ApoE(genotype( O0.038( 0.174( O0.220( 0.826( O0.380( 0.303(
((Brain(area:( *STG( 5.785( 1.229( 4.710( <0.001( 3.376( 8.194(














Variable( Coefficient( Std.(Err.( Z( p! 95%(CI(
*AD(status( 2.682( 1.354( 1.980( 0.048( 0.029( 5.335(
((Sex( 1.787( 1.209( 1.480( 0.139( O0.583( 4.157(
((Age(at(death( 0.102( 0.061( 1.660( 0.097( O0.019( 0.222(
((ApoE(genotype( 0.028( 0.111( 0.250( 0.800( O0.190( 0.246(
((Brain(area:( *STG( O1.910( 0.904( O2.110( 0.035( O3.683( O0.137(





Variable( Coefficient( Std.(Err.( Z( p! 95%(CI(
*Braak staging( 0.834( 0.299( 2.790( 0.005( 0.248( 1.420(
*Sex( 2.587( 1.219( 2.120( 0.034( 0.197( 4.977(
((Age(at(death( 0.062( 0.062( 1.000( 0.315( O0.059( 0.184(
((ApoE(genotype( 0.014( 0.109( 0.130( 0.897( O0.199( 0.227(
((Brain(area:( *STG( O1.853( 0.909( O2.040( 0.042( O3.635( O0.070(
























































































































































































































































































































































































































































































































































39 -383733- - -31-302926- -24 -19 - - - -12 - - - - - -11106 - - -54321
T(+) 1 bp 471 bp
403938373635343323130292827262524232212019181716151413121110987654321
C(+) 1 bp 471 bp
1 2 3 4 - 6 7 - - - 11 12 13 14 15- 17 18 - 20 21 - - - - 26- 28 - 30 - - - - - - 37 38 39 -
T(-) 1 bp 471 bp
1 2 3 4 5 6 78 9 10 11 12 13 14 1516 17 18 19 20 21 223 24 25 2627 28 29 30 3132 33 4 3536 37 38 3940
C(-) 1 bp 471 bp
A GGAA GAG AGT ACT GCTA GGT CCC AGG AAGA AAG AGA GAG CAGC TTT CGG GAT GGGG ACG ATG GGG AGGT GTC CGA GGT CAAG AGA AAG CGG CACG AGC AGA CCC CTGT GTG CCG TCCT GTG GGC GCG GGGC GGC AGG GGA GGCG CAC ACC TGC TCCT TTG TGC AGC CTCC CCC CTC CCG CAAA GTT AAA GAG CAGG AAA GTC AGG ATTC CTC GCT CGG CCCT GCC CTG CCG GCTG CTC CGC GCT CCGC TCC TCC CTG CGAG CGT GTG TGT GTGT CGG GGG TCC CTCC CCT CCT GGC TCTG GGG TCG GGC GCGC ACC CCG CCC CGTA GCG CGG CCC CTCC CTG GCG AGC GCAA CCC CAT CCA GCGG GAG CGC GGA GCCG CGG CCG CGG GGAA GCA TTA AGT TTAT TCG CCT CAA AGTG ACG CAA AAA TTCT TCA AGA GCTC TTT GGC GGC GGCT ATC TAG AGA TCAG ACC ATG TGA GGGC CAG CCT TCT CCC
inSilico Assay Prediction
Nucleotide position (bp)
40 -39383736353431 - -302927 -25 -23 -2219 - -17-161513-9 - - -3 - - - - -1 -
T(+) 1 bp 425 bp
4140393837363534333231302928272625242322212019181716151413121110987654321
C(+) 1 bp 425 bp
1 - 3 - - - - 8 - - - 12 - - - 16 17- 19 20 21 - 23 24 25 26 - 28 - 30 - 32 - 34 35 36 37 - 39 40 -
T(-) 1 bp 425 bp
12 3 4 5 6 7 8 9 1011 12 1314 15 16 1718 19 20 21 22 23 24 25 26 27 28 29 30 31 3233 34 35 36 37 38 39 40 41
C(-) 1 bp 425 bp







































































































































Variable( Coefficient( Std.(Err.( Z( p# 95%(CI(
((AD(status( 0.0018( 0.0025( 0.7200( 0.4710( W0.0031( 0.0068(
((Sex( W0.0042( 0.0023( W1.8100( 0.0700( W0.0088( 0.0003(
*Age(at(death( 0.0004( 0.0001( 3.6900( <0.0001( 0.0002( 0.0007(
((ApoE(genotype( W0.0001( 0.0002( W0.5300( 0.5950( W0.0005( 0.0003(
((Brain(region:( *BA9( 0.0071( 0.0028( 2.5400( 0.0110( 0.0016( 0.0126(
( ((BA10( 0.0032( 0.0029( 1.1300( 0.2590( W0.0024( 0.0089(
( *BA46( 0.0078( 0.0030( 2.5600( 0.0100( 0.0018( 0.0137(
( *BA8( 0.0077( 0.0030( 2.6200( 0.0090( 0.0019( 0.0135(
( ((EC( 0.0046( 0.0032( 1.4500( 0.1480( W0.0016( 0.0109(



































































































































































































































































































































































































































































Variable( Coefficient( Std.(Err.( Z( p# 95%(CI(
((AD(status( 0.0020( 0.0021( 0.9600( 0.3370( W0.0021( 0.0061(
((Sex( 0.0014( 0.0019( 0.7200( 0.4690( W0.0023( 0.0051(
((Age(at(death( 0.0001( 0.0001( 1.3600( 0.1720( W0.0001( 0.0003(
((ApoE(genotype( 0.0000( 0.0001( 0.1300( 0.8970( W0.0003( 0.0003(
((Brain(region:( ((BA9( 0.0021( 0.0026( 0.8100( 0.4190( W0.0030( 0.0072(
( ((BA10( 0.0012( 0.0027( 0.4600( 0.6490( W0.0040( 0.0065(
( ((BA46( 0.0026( 0.0028( 0.9300( 0.3500( W0.0029( 0.0082(
( ((BA8( 0.0048( 0.0028( 1.7100( 0.0870( W0.0007( 0.0102(
( ((EC( 0.0003( 0.0029( 0.1000( 0.9210( W0.0055( 0.0060(






Variable( Coefficient( Std.(Err.( Z( p# 95%(CI(
((AD(status( 0.0013( 0.0038( 0.3400( 0.7320( W0.0061( 0.0087(
*Sex( W0.0069( 0.0035( W1.9900( 0.0470( W0.0138( W0.0001(
*Age(at(death( 0.0008( 0.0002( 4.2900( <0.0001( 0.0004( 0.0011(
((ApoE(genotype( W0.0001( 0.0003( W0.2700( 0.7850( W0.0006( 0.0005(
((Brain(region:( *BA9( 0.0127( 0.0047( 2.7100( 0.0070( 0.0035( 0.0219(
( ((BA10( 0.0078( 0.0048( 1.6400( 0.1010( W0.0015( 0.0172(
( *BA46( 0.0122( 0.0050( 2.4300( 0.0150( 0.0024( 0.0220(
( ((BA8( 0.0092( 0.0048( 1.9000( 0.0570( W0.0003( 0.0186(
( ((EC( 0.0086( 0.0051( 1.6700( 0.0940( W0.0015( 0.0186(


































































































































































































































































































































































































Variable( Coefficient( Std.(Err.( Z( p# 95%(CI(
((AD(status( W0.029( 0.121( W0.240( 0.811( W0.266( 0.209(
*Average(CGI(methylation( 7.149( 2.432( 2.940( 0.003( 2.382( 11.916(
((Sex( 0.173( 0.118( 1.470( 0.142( W0.058( 0.405(
((Age(at(death( W0.009( 0.006( W1.520( 0.129( W0.021( 0.003(
((ApoE(genotype( 0.013( 0.009( 1.430( 0.153( W0.005( 0.030(
((Brain(region:( *BA9( 0.988( 0.122( 8.070( <0.001( 0.748( 1.228(
( ((BA10( W0.154( 0.127( W1.210( 0.227( W0.403( 0.096(
( ((BA46( W0.167( 0.139( W1.200( 0.229( W0.439( 0.105(
( *BA8( W0.355( 0.131( W2.700( 0.007( W0.612( W0.097(
( *EC( W1.030( 0.147( W7.030( <0.001( W1.317( W0.743(
































Variable( Coefficient( Std.(Err.( Z( p# 95%(CI(
((AD(status( W0.017( 0.106( W0.160( 0.876( W0.224( 0.191(
*Average(CGI(methylation(amplicon(1( 5.136( 2.314( 2.220( 0.026( 0.602( 9.671(
((Sex( 0.134( 0.102( 1.320( 0.187( W0.065( 0.334(
((Age(at(death( W0.010( 0.005( W1.950( 0.051( W0.020( 0.000(
((ApoE(genotype( 0.014( 0.008( 1.810( 0.070( W0.001( 0.029(
((Brain(region:( *BA9( 1.090( 0.110( 9.870( <0.001( 0.874( 1.307(
( ((BA10( W0.100( 0.120( W0.830( 0.404( W0.335( 0.135(
( ((BA46( W0.085( 0.127( W0.670( 0.503( W0.333( 0.163(
( *BA8( W0.276( 0.123( W2.240( 0.025( W0.517( W0.035(
( *EC( W1.001( 0.137( W7.330( <0.001( W1.269( W0.733(







Variable( Coefficient( Std.(Err.( Z( p# 95%(CI(
((AD(status( W0.056( 0.118( W0.480( 0.633( W0.288( 0.175(
((Average(CGI(methylation(amplicon(2( 2.728( 1.443( 1.890( 0.059( W0.100( 5.555(
((Sex( 0.191( 0.116( 1.650( 0.099( W0.036( 0.419(
((Age(at(death( W0.008( 0.006( W1.290( 0.197( W0.020( 0.004(
((ApoE(genotype( 0.013( 0.009( 1.530( 0.127( W0.004( 0.031(
((Brain(region:( *BA9( 1.129( 0.123( 9.180( <0.001( 0.888( 1.370(
( ((BA10( W0.069( 0.129( W0.530( 0.595( W0.321( 0.184(
( ((BA46( W0.040( 0.141( W0.280( 0.776( W0.315( 0.235(
( ((BA8( W0.207( 0.133( W1.560( 0.119( W0.468( 0.053(
( *EC( W0.945( 0.149( W6.360( <0.001( W1.236( W0.654(












































Variable( Mean( Std.(Dev.( Range(
Age(at(death((years)( 86.6( 7.4( 69W98(
Age(at(score((years)( 83.4( 7.6( 65W95(
Disease(duration((years)( 9.1( 3.7( 0W19(
Disease(duration(at(score((years)( 6.7( 3.5( 1.5W15(
CSDD(score( 9.3( 5.8( 0W22(
SERT(mRNA(levels((log)( 2.05( 0.86( W0.19W4.49(










( 0(short(S(alleles( 8( 25(
5HTTLPR( 1(short(S(allele( 19( 59(
( 2(short(S(alleles( 5( 16(
( Severe(impairment( 15( 46.9(
MMSE( Moderate(W(severe(impairment( 10( 31.25(
( Mild(W(moderate(impairment( 7( 21.9(
( <9(years( 16( 50(
Education( 9W12(years( 12( 37.5(






































Variable( Coefficient( Std.(Err.( t( p# 95%(CI(
((Age(at(score( W0.028( 0.054( W0.520( 0.606( W0.134( 0.078(
*Sex( W1.829( 0.867( W2.110( 0.036( W3.538( W0.120(
*ApoE(genotype( W0.245( 0.060( W4.070( <0.001( W0.364( W0.126(
((Antipsychotics( 0.774( 0.918( 0.840( 0.400( W1.035( 2.583(
*Antidepressants( 6.734( 1.115( 6.040( 0.000( 4.537( 8.932(
((MMSE(category( W0.189( 0.457( W0.410( 0.679( W1.089( 0.710(
*Disease(duration( 0.020( 0.008( 2.350( 0.019( 0.003( 0.037(
*SLE( W3.033( 0.888( W3.410( 0.001( W4.783( W1.282(
*5HTTLPR(S/S(genotype( W2.439( 1.007( W2.420( 0.016( W4.424( W0.454(




















Variable( Coefficient( Std.(Err.( Z( p# 95%(CI(
((CSDD(score( 0.0005( 0.0003( 1.8600( 0.0620( 0.0000( 0.0010(
*SLE( 0.0069( 0.0034( 2.0700( 0.0380( 0.0004( 0.0135(
((5HTTLPR(S/S(genotype( W0.0011( 0.0041( W0.2700( 0.7870( W0.0092( 0.0070(
*Age(at(death( 0.0005( 0.0002( 2.5000( 0.0120( 0.0001( 0.0009(
((Sex( W0.0002( 0.0034( W0.0700( 0.9470( W0.0068( 0.0064(
((ApoE(genotype( 0.0002( 0.0002( 1.1000( 0.2720( W0.0002( 0.0007(
((Antidepressants( W0.0050( 0.0040( W1.2500( 0.2100( W0.0128( 0.0028(
((Disease(duration( W0.0002( 0.0004( W0.3900( 0.6930( W0.0009( 0.0006(
((Brain(region:( ((BA9( 0.0035( 0.0031( 1.1200( 0.2650( W0.0026( 0.0096(
( ((BA10( 0.0029( 0.0032( 0.8900( 0.3750( W0.0035( 0.0092(
( ((BA46( 0.0035( 0.0035( 0.9800( 0.3280( W0.0035( 0.0104(
( *BA8( 0.0074( 0.0037( 1.9800( 0.0470( 0.0001( 0.0146(
( ((EC( 0.0057( 0.0042( 1.3800( 0.1660( W0.0024( 0.0139(
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Variable( Coefficient( Std.(Err.( Z( p# 95%(CI(
(CSDD(score( 0.0002( 0.0002( 0.8000( 0.4260( W0.0003( 0.0007(
(SLE( W0.0008( 0.0032( W0.2600( 0.7980( W0.0071( 0.0055(
(5HTTLPR(S/S(genotype( W0.0018( 0.0038( W0.4600( 0.6470( W0.0093( 0.0058(
(Age(at(death( 0.0003( 0.0002( 1.6400( 0.1000( W0.0001( 0.0007(
(Sex( 0.0013( 0.0032( 0.4200( 0.6770( W0.0049( 0.0076(
(ApoE(genotype( 0.0000( 0.0002( 0.1300( 0.8950( W0.0004( 0.0004(
(Antidepressants( W0.0060( 0.0038( W1.5800( 0.1130( W0.0133( 0.0014(
(Disease(duration( W0.0003( 0.0004( W0.7200( 0.4740( W0.0010( 0.0005(
(Brain(region:( ((BA9( W0.0003( 0.0035( W0.0800( 0.9360( W0.0072( 0.0066(
( ((BA10( 0.0040( 0.0035( 1.1500( 0.2510( W0.0029( 0.0109(
( ((BA46( 0.0051( 0.0037( 1.3700( 0.1720( W0.0022( 0.0123(
( *BA8( 0.0073( 0.0037( 1.9700( 0.0480( 0.0001( 0.0146(
( ((EC( 0.0012( 0.0039( 0.3100( 0.7570( W0.0065( 0.0089(







Variable( Coefficient( Std.(Err.( Z( p# 95%(CI(
*CSDD(score( 0.0008( 0.0003( 2.4400( 0.0150( 0.0002( 0.0015(
*SLE( 0.0103( 0.0044( 2.3200( 0.0200( 0.0016( 0.0190(
((5HTTLPR(S/S(genotype( W0.0038( 0.0057( W0.6700( 0.5000( W0.0149( 0.0073(
*Age(at(death( 0.0009( 0.0003( 3.0000( 0.0030( 0.0003( 0.0014(
((Sex( 0.0004( 0.0045( 0.0900( 0.9310( W0.0085( 0.0093(
((ApoE(genotype( 0.0004( 0.0003( 1.4900( 0.1370( W0.0001( 0.0010(
((Antidepressants( W0.0045( 0.0053( W0.8500( 0.3950( W0.0150( 0.0059(
((Disease(duration( 0.0000( 0.0005( 0.0900( 0.9300( W0.0010( 0.0011(
((Brain(region:( ((BA9( 0.0084( 0.0049( 1.7100( 0.0870( W0.0012( 0.0181(
( ((BA10( 0.0041( 0.0051( 0.8100( 0.4170( W0.0059( 0.0141(
( ((BA46( 0.0038( 0.0054( 0.7100( 0.4750( W0.0067( 0.0144(
( ((BA8( 0.0105( 0.0054( 1.9500( 0.0510( W0.0001( 0.0211(
( ((EC( 0.0059( 0.0058( 1.0300( 0.3040( W0.0054( 0.0173(










































































Variable( Coefficient( Std.(Err.( Z( p# 95%(CI(
*Average(CGI(methylation( 7.000( 3.391( 2.060( 0.039( 0.354( 13.646(
*CSDD(score( 0.034( 0.011( 3.040( 0.002( 0.012( 0.056(
*5HTTLPR(S/S(genotype( W0.446( 0.179( W2.490( 0.013( W0.796( W0.095(
*Age(at(death( 0.018( 0.009( 2.040( 0.042( 0.001( 0.036(
((Sex( 0.163( 0.138( 1.190( 0.236( W0.107( 0.433(
((ApoE(genotype( 0.012( 0.009( 1.350( 0.176( W0.006( 0.030(
*Antidepressants( W0.425( 0.162( W2.620( 0.009( W0.743( W0.108(
((Disease(duration( 0.010( 0.015( 0.680( 0.498( W0.020( 0.041(
((Brain(region:( *BA9( 0.942( 0.142( 6.620( <0.001( 0.663( 1.221(
( ((BA10( W0.268( 0.153( W1.760( 0.079( W0.568( 0.031(
( ((BA46( W0.186( 0.166( W1.120( 0.264( W0.511( 0.140(
( *BA8( W0.422( 0.165( W2.550( 0.011( W0.746( W0.098(
( *EC( W1.284( 0.194( W6.630( <0.001( W1.664( W0.904(















Variable( Coefficient( Std.(Err.( Z( p# 95%(CI(
*Average(CGI(methylation(amplicon(1( 7.446( 3.297( 2.260( 0.024( 0.984( 13.907(
((Average(CGI(methylation(amplicon(2( 2.185( 2.068( 1.060( 0.291( W1.867( 6.237(
*CSDD(score( 0.034( 0.011( 2.990( 0.003( 0.012( 0.056(
*5HTTLPR(S/S(genotype( W0.470( 0.181( W2.600( 0.009( W0.824( W0.115(
*Age(at(death( 0.018( 0.009( 2.020( 0.044( 0.001( 0.036(
((Sex( 0.155( 0.139( 1.110( 0.265( W0.117( 0.427(
((ApoE(genotype( 0.012( 0.009( 1.350( 0.178( W0.006( 0.031(
*Antidepressants( W0.407( 0.163( W2.490( 0.013( W0.727( W0.086(
((Disease(duration( 0.012( 0.015( 0.780( 0.438( W0.018( 0.042(
((Brain(region:( *BA9( 0.968( 0.142( 6.810( <0.001( 0.689( 1.247(
( ((BA10( W0.281( 0.152( W1.850( 0.064( W0.579( 0.017(
( ((BA46( W0.190( 0.165( W1.150( 0.251( W0.513( 0.134(
( *BA8( W0.430( 0.165( W2.610( 0.009( W0.753( W0.107(
( *EC( W1.338( 0.191( W7.000( <0.001( W1.713( W0.964(






























































































































































































































































































































































































































































































































































































































 ROI (Brohede et al. 2010) 
 ROI (Tohgi et al. 1999 & Nagane et al. 2000) 
 Observed DMR (Nagane et al. 2000) 
 Observed DMR (Tohgi et al. 1999) 
 ROI (Barrachina & Ferrer 2009) 
 ROI (Wang et al. 2008) 
 ROI (Milici et al. 1990) 
 ROI (Rogaev et al. 1994) 
 Observed DMR (Rogaev et al. 1994) 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Total(methylated(C's(in(CpG(context( 1551655( 1322299( 4053082( 103264(
Total(C(to(T(conversions(in(CpG(context( 3231231( 2627722( 292312( 6286457(
































































































ROI (f68) ROI (f77)
ROI (f14) ROI (f28)
Chapter(5(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((APP(gene(bisulphite(sequencing(
 169(
Methylation(ROI( Coefficient( Std.(Err.( t( p( 95%(CI(
IVS1((f45)( X0.303( 0.112( X2.71( 0.008( X0.525( X0.080(
IVS1_Enhancer(4((f68)( X5.364( 2.346( X2.29( 0.025( X10.036( X0.692(
IVS2_Open(Chromatin(3((f77)( X6.398( 2.899( X2.21( 0.030( X12.172( X0.625(
IVS13((f14)( X5.529( 2.502( X2.21( 0.030( X10.512( X0.547(





Methylation(ROI( Coefficient( Std.(Err.( t( p( 95%(CI(
IVS3((f79)( X0.177( 0.088( X2.03( 0.046( X0.352( X0.003(
IVS3_Open(Chromatin(4((f81)( X0.135( 0.060( X2.25( 0.027( X0.255( X0.016(
IVS3_Open(Chromatin(4((f82)( 0.116( 0.052( 2.25( 0.027( 0.013( 0.219(
Exon(5((f86)( 0.168( 0.071( 2.37( 0.020( 0.027( 0.309(
Exon(11((f102)( 0.571( 0.188( 3.03( 0.004( 0.193( 0.948(
IVS11((f106)( 0.227( 0.084( 2.69( 0.009( 0.058( 0.395(


































Methylation(Feature( Coefficient( Std.(Err.( t( PXvalue( 95%(CI(
CGI(Shore(5'( 0.788( 3.19( 0.25( 0.806( X5.574( 7.149(
5’(region ( 0.116( 2.064( 0.06( 0.955( X3.997( 4.23(
CGI( X0.441( 0.287( X1.53( 0.129( X1.012( 0.131(
CGI(Shore(3'( X2.229( 4.271( X0.52( 0.603( X10.74( 6.281(
Enhancer( X0.124( 1.138( X0.11( 0.914( X2.391( 2.143(
Exon( X0.156( 0.966( X0.16( 0.872( X2.08( 1.768(
IVS( X1.185( 0.812( X1.46( 0.149( X2.802( 0.433(
Open(Chromatin( X0.784( 1.237( X0.63( 0.528( X3.248( 1.681(
Alu( X0.12( 0.843( X0.14( 0.887( X1.801( 1.561(
MIRb( 1.964( 7.52( 0.26( 0.795( X13.055( 16.983(
3’UTR( 0.421( 1.204( 0.35( 0.728( X1.977( 2.819(















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Methylation(CpG( Coefficient( Std.(Err.( t( PXvalue( Corrected(PXvalue( 95%(CI(
5'(region(CGI(shore((c1)( 7.481( 3.212( 2.33( 0.023( 0.276( 1.076( 13.886(
5'(region((c2)( 7.359( 6.16( 1.19( 0.237( 2.844( X4.98( 19.698(
5'(region((c3)( 6.458( 4.935( 1.31( 0.196( 2.352( X3.428( 16.344(
IVS1_Enhancer(3((c147)( X3.029( 2.696( X1.12( 0.265( 3.180( X8.403( 2.344(
IVS1_Enhancer(3((c148)( X3.086( 2.714( X1.14( 0.259( 3.108( X8.497( 2.325(
IVS1_Enhancer(3((c149)( X1.899( 2.58( X0.74( 0.464( 5.568( X7.043( 3.245(
Exon(5((c195)( 5.275( 1.938( 2.72( 0.008( 0.096( 1.414( 9.137(
Exon(5((c196)( 4.582( 1.927( 2.38( 0.020( 0.240( 0.743( 8.421(
Exon(5((c197)( 5.582( 2.312( 2.41( 0.018( 0.216( 0.975( 10.19(
Exon(11((c225)( 0.039( 5.707( 0.01( 0.995( 11.94( X11.413( 11.49(
IVS11((c226)( 1.859( 5.251( 0.35( 0.725( 8.700( X8.678( 12.396(































































































































































































































ENCODE Enhancer- and Promoter-Associated Histone Mark (H3K4Me1) on 8 Cell Lines
rs466433rs364048
-877T/C-955A/G














ENCODE Digital DNaseI Hypersensitivity Clusters
ENCODE Transcription Factor ChIP-seq
ENCODE Enhancer- and Promoter-Associated Histon  Mark (H3K4Me1) on 8 Cell Lines
ENCODE Enhancer- and Promoter-Associated Histone Mark (H3K27Ac) on 8 Cell Lines
















































































c5( 5’(region( 38.61( 5( 52.1( 13.29( 0.169( 0.122(
c12( 5'(region( 7.88( 1.63( 0.36( 0.48( X0.098( 0.403(
c21( CGI( 4.2( 0.64( 3.01( 5( X0.01( 0.932(
c35( Exon1( 5.36( 0.79( 0.43( 0.28( X0.217( 0.101(
c58( CGI( 19.7( 2.42( 0.22( 0.12( 0.214( 0.052(
c64( CGI( 2.52( 0.38( 0.28( 0.68( X0.108( 0.353(
c116( CGI( 8.17( 0.83( 0.32( 1.01( 0.061( 0.57(
c131( IVS1(Enhancer(1( 40.39( 3.46( 35.18( 7.84( 0.305( 0.003(
c135( IVS1(Enhancer(1( 31.61( 4.33( 20.93( 12.04( 0.256( 0.025(
c139( IVS1(Enhancer(1( 40.42( 4.65( 22.79( 11.63( 0.252( 0.027(
c204( Exon(7( 76.47( 3.27( 76.94( 9.87( 0.169( 0.108(
c205( Exon(7( 85.82( 2.57( 83.95( 8.31( 0.147( 0.163(
c207( Exon(7( 80.86( 3.32( 83.77( 20.06( 0.021( 0.848(
c208( Exon(7( 81.41( 3.12( 90.08( 16.01( 0.188( 0.079(
c221( Exon(9( 85.8( 1.41( 91.18( 9.89( 0.078( 0.596(

























Methylation(CpG( Coefficient( Std.(Err.( t( PXvalue( Corrected(PXvalue( 95%(CI(
5’(region(CGI(shore((AR11)( 0.400( 1.080( 0.37( 0.712( 15.664( X1.751( 2.552(
5’(region (c5)( 2.173( 1.385( 1.57( 0.121( 2.662( X0.586( 4.931(
5’(region (c12)( X0.369( 0.450( X0.82( 0.416( 9.152( X1.266( 0.529(
CGI((c21)( 0.130( 0.178( 0.73( 0.466( 10.252( X0.224( 0.484(
CGI((AR8)( 0.332( 0.217( 1.53( 0.130( 2.860( X0.101( 0.765(
CGI((AR3)( 0.323( 0.146( 2.21( 0.030( 0.660( 0.031( 0.614(
CGI((AR2)( 0.160( 0.183( 0.87( 0.387( 8.514( X0.206( 0.525(
Exon1((c35)( X0.198( 0.216( X0.92( 0.362( 7.964( X0.628( 0.232(
CGI((c58)( 1.197( 0.665( 1.80( 0.076( 1.672( X0.127( 2.522(
CGI((c64)( X0.022( 0.108( X0.21( 0.836( 18.392( X0.238( 0.194(
CGI((c116)( 0.339( 0.231( 1.47( 0.146( 3.212( X0.121( 0.799(
IVS1(Enhancer(1((c131)( X0.608( 0.982( X0.62( 0.538( 11.836( X2.565( 1.349(
IVS1(Enhancer(1((c135)( X0.837( 1.210( X0.69( 0.491( 10.802( X3.249( 1.574(
IVS1(Enhancer(1((c139)( X0.527( 1.295( X0.41( 0.685( 15.07( X3.107( 2.053(
IVS1((AR10)( 2.103( 0.861( 2.44( 0.017( 0.374( 0.388( 3.818(
Exon(7((c204)( X0.653( 0.913( X0.71( 0.477( 10.494( X2.473( 1.168(
Exon(7((c205)( 0.888( 0.705( 1.26( 0.212( 4.664( X0.517( 2.294(
Exon(7((c207)( 1.250( 0.887( 1.41( 0.163( 3.586( X0.516( 3.017(
Exon(7((c208)( 1.345( 0.846( 1.59( 0.116( 2.552( X0.341( 3.03(
Exon(9((c221)( 0.141( 0.395( 0.36( 0.723( 15.906( X0.647( 0.928(
IVS13((AR22)( X0.188( 0.691( X0.27( 0.786( 17.292( X1.566( 1.189(









































































































































































































































































































































































bSNP(1( IVS4((f85)( rs6516719( C/T( +(
bSNP(2( IVS11((f107)( rs440666( T/C( +(
bSNP(3( IVS1_Enhancer(3((f61)( rs2830071( C/T( +(
bSNP(4( IVS1_Enhancer(3((f62)( rs2830070( T/C( +(
bSNP(5( IVS2_Open(Chromatn(3((f77)( rs2830052( C/T( +(
bSNP(6( IVS13((f6d)( rs2829996( T/A( +(
bSNP(7( IVS17_Open(Chromatin(10((f27)( rs214485( C/A( +(
bSNP(8( IVS13((f6)( rs190392435( T/C( X(
bSNP(9( IVS1_Open(Chromatn(2((f65)( rs181441239( T/C( X(
bSNP(10( IVS13((f6d)( rs1701001( C/T( +(
bSNP(11( Exon(9((f99)( rs148257054( T/C( X(
bSNP(12( IVS1_Enhancer(1((f52)( rs147054581( C/T( +(
bSNP(13( IVS16((f20)( rs144506349( T/C( X(
bSNP(14( IVS1((f46)( rs139326696( T/A( X(
bSNP(15( IVS7_Open(Chromatn(6((f94)( rs139128431( T/C( +(
bSNP(16( IVS3_Open(Chromatn(4((f81)( rs12626415( C/T( +(
bSNP(17( IVS1_Enhancer(2((f57)( rs117982323( C/A( +(
bSNP(18( IVS10((f100)( rs115962715( T/C( X(
bSNP(19( Exon(14((f16)( rs112263157( T/C( X(



































IVS4((c194)( bSNP(1( rs6516719( C/T( 5.76(x(10X30( 1.56(x(10X27(
IVS12((c245)( aSNP(19( rs417676( G/A( 2.00(x(10X16( 5.42(x(10X14(
IVS12((f4)( aSNP(19( rs417676( G/A( 6.74(x(10X16( 1.83(x(10X13(
IVS4((f85)( bSNP(1( rs6516719( C/T( 3.74(x(10X14( 1.01(x(10X11(
IVS2_Open(Chromatin(3((f77)( bSNP(5( rs2830052( C/T( 7.70(x(10X09( 2.09(x(10X06(
IVS17_Open(Chromatin10((c289)( bSNP(7( rs214485( C/A( 5.22(x(10X06( 1.41(x(10X03(
5’(region (f93)( aSNP(7( rs139885956( G/A( 8.48(x(10X04( 2.30(x(10X01(
5’(region (c6)( aSNP(7( rs139885956( G/A( 3.30(x(10X03( 8.94(x(10X01(
5’(region (c7)( aSNP(7( rs139885956( G/A( 4.82(x(10X03( 1.31(
CGI((c80)( aSNP(53( rs117107800( C/G( 7.48(x(10X03( 2.03(
IVS1_Enhancer(4((c159)( aSNP(48( rs13048354( C/T( 7.69(x(10X03( 2.08(
CGI((c71)( aSNP(53( rs117107800( C/G( 7.71(x(10X03( 2.09(
CGI((c75)( aSNP(53( rs117107800( C/G( 2.13(x(10X02( 5.77(
CGI((c100)( aSNP(28( rs469420( A/G( 2.16(x(10X02( 5.85(
IVS13_Open(Chromatin(8((c259)( aSNP(1( rs116967391( G/C( 2.31(x(10X02( 6.26(
CGI((c79)( aSNP(53( rs117107800( C/G( 2.68(x(10X02( 7.26(
IVS1_Open(Chromatin(2((c154)( bSNP(9( rs181441239( T/C( 2.86(x(10X02( 7.75(
CGI((c109)( aSNP(21( rs45473297( G/A( 3.29(x(10X02( 8.91(
CGI((c103)( aSNP(21( rs45473297( G/A( 4.46(x(10X02( 12.09(
IVS13((f6)( bSNP(6( rs2829996( T/A( 4.59(x(10X02( 12.44(










































































































ENCODE Transcription Factor ChIP-seq






























































ENCODE Transcription Factor ChIP-seq


















































































ENCODE Transcription Factor ChIP-seq
ENCODE Digital DNaseI Hypersensitivity Clusters
Wiki Track user annotati ns
bSNP7_rs214485
IVS17_OpenChromatin10_(c289)













ENCODE Transcription Factor ChIP-seq
ENCODE Digital DNaseI Hypersensitivity Clusters
Wiki Track user annotations
bSNP7_rs214485
IVS17_OpenChromatin10_(c289)














ENCODE Transcription Factor ChIP-seq

















































ENCODE Transcription Factor ChIP-seq
Significant Methylation Sites















ENCODE Transcription Factor ChIP-seq
Significant Methylation Sites



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Disease!Status! Sex! Age! ApoE!Genotype! Braak!Stage! Sample!ID!
AD! Female! 96! 3,4! 4! 8!
AD! Female! 92! 3,4! 6! 9!
AD! Female! 89! 3,3! 6! 11!
AD! Female! 80! 3,4! 5! 13!
AD! Female! 91! 3,4! 3! 16!
AD! Female! 84! 3,4! 6! 17!
AD! Female! 82! 4,4! 6! 18!
AD! Female! 81! 3,4! ]! 19!
AD! Female! 69! 3,3! 6! 20!
AD! Female! 90! 3,3! ]! 21!
AD! Female! 91! 4,4! 6! 22!
AD! Female! 96! 4,4! 5! 23!
AD! Female! 85! 4,4! 5! 24!
AD! Female! 97! 3,3! 5! 25!
AD! Female! 87! 3,3! 3! 26!
AD! Female! 85! 3,3! 6! 27!
AD! Female! 87! 2,4! 6! 29!
AD! Female! 91! 2,4! 5! 31!
AD! Female! 92! 3,4! 6! 33!
AD! Female! 94! 4,4! 5! 35!
AD! Female! 88! 3,4! 6! 38!
AD! Female! 90! 3,4! 6! 39!
AD! Female! 80! 4,4! 6! 40!
AD! Female! 93! 3,4! 6! 41!
AD! Female! 73! 3,3! 0! 54!
AD! Female! 98! 3,3! 3! 57!
AD! Female! 98! 3,4! 6! 59!
AD! Male! 89! 3,3! ]! 3!
AD! Male! 82! 3,3! 6! 10!
AD! Male! 91! 3,3! 6! 12!
AD! Male! 89! 2,3! ]! 14!
AD! Male! 84! 4,4! 6! 15!
AD! Male! 80! 3,4! 6! 30!
AD! Male! 81! 4,4! 6! 32!
! 230!
AD! Male! 71! 2,3! 6! 34!
AD! Male! 90! 3,4! 6! 36!
AD! Male! 86! 2,4! 5! 37!
AD! Male! 80! 3,4! 3! 56!
AD! Male! 72! 3,3! 6! 58!
Ctrl! Female! 82! 3,3! 0! 1!
Ctrl! Female! 82! 2,3! 2! 2!
Ctrl! Female! 81! 3,3! 1! 4!
Ctrl! Female! 92! 3,3! 2! 5!
Ctrl! Female! 80! 3,3! 0! 28!
Ctrl! Female! 55! 3,3! 1! 42!
Ctrl! Female! 88! 3,4! 5! 45!
Ctrl! Female! 87! 3,3! 0! 48!
Ctrl! Female! 68! ],]! 0! 49!
Ctrl! Female! 80! 3,4! 5! 51!
Ctrl! Female! 90! 3,3! 2! 61!
Ctrl! Female! 88! 3,3! 6! 64!
Ctrl! Female! 90! 2,3! 3! 69!
Ctrl! Female! 89! 3,3! 4! 77!
Ctrl! Female! 92! 3,4! 1! 94!
Ctrl! Male! 78! 2,3! 1! 6!
Ctrl! Male! 86! 3,4! 3! 7!
Ctrl! Male! 79! 2,3! 2! 43!
Ctrl! Male! 80! 3,3! 1! 44!
Ctrl! Male! 86! 3,3! 0! 47!
Ctrl! Male! 59! 4,4! 0! 50!
Ctrl! Male! 40! 3,4! 0! 52!
Ctrl! Male! 81! 2,4! 3! 60!
Ctrl! Male! 81! 3,3! 1! 62!
Ctrl! Male! 66! 3,3! 1! 63!
Ctrl! Male! 86! 3,3! 3! 65!






Disease!Status! Sex! Age! ApoE!Genotype! Braak!Stage! Sample!ID!
AD! Female! 80! 3,4! 5! 13!
AD! Female! 88! 3,4! 6! 38!
AD! Female! 80! 4,4! 6! 40!
AD! Female! 96! 3,4! 4! 8!
AD! Female! 92! 3,4! 6! 9!
AD! Female! 89! 3,3! 6! 11!
! 231!
AD! Female! 91! 3,4! 3! 16!
AD! Female! 84! 4,4! 6! 17!
AD! Female! 81! 3,4! ]! 19!
AD! Female! 69! 3,3! 6! 20!
AD! Female! 90! 3,3! ]! 21!
AD! Female! 96! 4,4! 5! 23!
AD! Female! 85! 4,4! 5! 24!
AD! Female! 97! 3,3! 5! 25!
AD! Female! 87! 3,3! 3! 26!
AD! Female! 87! 2,4! 6! 29!
AD! Female! 91! 2,4! 5! 31!
AD! Female! 92! 3,4! 6! 33!
AD! Female! 94! 4,4! 5! 35!
AD! Female! 93! 3,4! 6! 41!
AD! Female! 98! 3,3! 3! 57!
AD! Female! 98! 3,4! 6! 59!
AD! Female! 82! 4,4! 6! 18!
AD! Female! 91! 4,4! 6! 22!
AD! Female! 85! 3,3! 6! 27!
AD! Female! 90! 3,4! 6! 39!
AD! Female! 73! 3,3! 0! 54!
AD! Male! 82! 3,3! 6! 10!
AD! Male! 84! 4,4! 6! 15!
AD! Male! 90! 3,4! 6! 36!
AD! Male! 86! 2,4! 5! 37!
AD! Male! 91! 3,3! 6! 12!
AD! Male! 89! 2,3! ]! 14!
AD! Male! 80! 3,4! 6! 30!
AD! Male! 81! 4,4! 6! 32!
AD! Male! 71! 2,3! 6! 34!
AD! Male! 72! 3,3! 6! 58!
Ctrl! Female! 82! 3,3! 0! 1!
Ctrl! Female! 82! 2,3! 2! 2!
Ctrl! Female! 81! 3,3! 1! 4!
Ctrl! Female! 92! 3,3! 2! 5!
Ctrl! Female! 80! 3,3! 0! 28!
Ctrl! Female! 55! 3,3! 1! 42!
Ctrl! Female! 88! 3,4! 5! 45!
Ctrl! Female! 87! 3,3! 0! 48!
Ctrl! Female! 68! ],]! 0! 49!
Ctrl! Female! 80! 3,4! 5! 51!
Ctrl! Female! 55! 3,4! 0! 53!
Ctrl! Female! 90! 3,3! 2! 61!
Ctrl! Male! 89! 3,3! ]! 3!
Ctrl! Male! 78! 2,3! ]! 6!
Ctrl! Male! 86! 3,4! 3! 7!
! 232!
Ctrl! Male! 79! 2,3! 2! 43!
Ctrl! Male! 80! 3,3! 1! 44!
Ctrl! Male! 78! 2,3! 1! 46!
Ctrl! Male! 86! 3,3! 0! 47!
Ctrl! Male! 59! 4,4! 0! 50!
Ctrl! Male! 40! 3,4! 0! 52!
Ctrl! Male! 80! 3,4! 3! 56!
Ctrl! Male! 81! 2,4! 3! 60!






Disease!Status! Sex! Age! ApoE!Genotype! Braak!Stage! Sample!ID! Passed!QC!
AD! Female! 82! 2,3! 2! 2! Yes!
AD! Female! 96! 3,4! 4! 8! Yes!
AD! Female! 90! 3,4! ]! 9! Yes!
AD! Female! 89! 3,3! 6! 11! Yes!
AD! Female! 80! 3,4! 5! 13! No!
AD! Female! 91! 3,4! 6! 16! Yes!
AD! Female! 84! 3,4! 6! 17! Yes!
AD! Female! 82! 4,4! 6! 18! No!
AD! Female! 81! 3,4! ]! 19! Yes!
AD! Female! 69! 3,3! 6! 20! Yes!
AD! Female! 90! 3,3! ]! 21! No!
AD! Female! 91! 4,4! 6! 22! Yes!
AD! Female! 96! 4,4! 5! 23! Yes!
AD! Female! 85! 4,4! 5! 24! Yes!
AD! Female! 97! 3,3! 5! 25! Yes!
AD! Female! 85! 3,3! 6! 27! Yes!
AD! Female! 87! 2,4! 6! 29! Yes!
AD! Female! 91! 2,4! 5! 31! Yes!
AD! Female! 92! 3,4! 6! 33! Yes!
AD! Female! 94! 4,4! 5! 35! Yes!
AD! Female! 88! 3,4! 6! 38! Yes!
AD! Female! 90! 3,4! 6! 39! Yes!
AD! Female! 80! 4,4! 6! 40! Yes!
AD! Female! 93! 3,4! 0! 41! Yes!
AD! Female! 98! 3,3! 3! 57! Yes!
AD! Female! 98! 3,4! 6! 59! Yes!
AD! Female! 87! 3,3! 3! 66! Yes!
AD! Female! 79! 3,4! 6! 75! No!
AD! Female! 85! 3,4! 6! 76! Yes!
! 233!
AD! Female! 89! 3,3! 4! 77! No!
AD! Female! 85! 3,4! 6! 79! Yes!
AD! Female! 84! 3,3! 4! 80! Yes!
AD! Female! 86! 3,4! 6! 81! Yes!
AD! Female! 103! 3,3! 5! 82! Yes!
AD! Female! 81! 3,4! 6! 85! Yes!
AD! Female! 83! 3,3! 3! 89! No!
AD! Female! 84! 3,4! 6! 91! Yes!
AD! Female! 92! 3,4! 5! 92! Yes!
AD! Female! 80! 4,4! 6! 96! Yes!
AD! Female! 98! 3,3! 6! 97! Yes!
AD! Female! 83! 3,4! 6! 106! Yes!
AD! Male! 89! 3,3! ]! 3! Yes!
AD! Male! 82! 3,3! ]! 10! Yes!
AD! Male! 91! 3,3! 6! 12! Yes!
AD! Male! 89! 2,3! ]! 14! Yes!
AD! Male! 84! 4,4! 6! 15! Yes!
AD! Male! 80! 3,4! 6! 30! Yes!
AD! Male! 81! 4,4! 6! 32! No!
AD! Male! 71! 2,3! 6! 34! Yes!
AD! Male! 90! 3,4! 6! 36! Yes!
AD! Male! 86! 2,4! 5! 37! Yes!
AD! Male! 80! 3,4! 3! 56! Yes!
AD! Male! 72! 3,3! 6! 58! Yes!
AD! Male! 81! 2,4! 3! 60! Yes!
AD! Male! 86! 3,3! 3! 65! Yes!
AD! Male! 82! 3,4! 4! 67! Yes!
AD! Male! 88! 3,4! 5! 71! Yes!
AD! Male! 80! 3,3! 6! 72! Yes!
AD! Male! 74! 3,4! 6! 83! Yes!
AD! Male! 88! 3,3! 6! 84! Yes!
AD! Male! 77! 3,4! 5! 86! Yes!
AD! Male! 86! 3,4! 6! 87! Yes!
AD! Male! 75! 4,4! 6! 88! No!
AD! Male! 97! 3,4! 5! 95! Yes!
AD! Male! 88! 2,4! 6! 100! Yes!
AD! Male! 105! 3,4! 5! 103! Yes!
Ctrl! Female! 82! 3,3! 0! 1! No!
Ctrl! Female! 81! 3,3! 1! 4! No!
Ctrl! Female! 92! 3,3! 2! 5! Yes!
Ctrl! Female! 80! 3,3! 0! 28! Yes!
Ctrl! Female! 55! 3,3! 0! 42! Yes!
Ctrl! Female! 88! 3,4! 5! 45! Yes!
Ctrl! Female! 87! 3,3! 0! 48! Yes!
Ctrl! Female! 68! ],]! 0! 49! Yes!
Ctrl! Female! 80! 3,4! 0! 51! Yes!
! 234!
Ctrl! Female! 55! 3,4! 0! 53! Yes!
Ctrl! Female! 73! 3,3! 0! 54! Yes!
Ctrl! Female! 90! 3,3! 2! 61! No!
Ctrl! Female! 88! 3,3! 6! 64! Yes!
Ctrl! Female! 90! 2,3! 3! 69! Yes!
Ctrl! Female! 85! 3,3! 1! 99! No!
Ctrl! Female! 94! ],]! 4! 102! Yes!
Ctrl! Female! 95! ],]! 5! 104! Yes!
Ctrl! Male! 86! 3,4! 3! 7! No!
Ctrl! Male! 79! 2,3! 2! 43! No!
Ctrl! Male! 80! 3,3! 0! 44! No!
Ctrl! Male! 78! 2,3! 1! 46! Yes!
Ctrl! Male! 86! 3,3! 0! 47! Yes!
Ctrl! Male! 59! 4,4! 0! 50! Yes!
Ctrl! Male! 40! 3,4! 0! 52! Yes!
Ctrl! Male! 81! 3,3! 1! 62! Yes!
Ctrl! Male! 66! 3,3! 0! 63! Yes!
Ctrl! Male! 86! 3,3! 3! 90! Yes!




































Array!set! Name! Forward!Sequence!(5’]3’)! Reverse!Sequence!(5’]3’)!
1! APP_3! GGAAAGAGAAATTGTTAAATTTAAGAAT! AATCAACACCATCCTAACTAACAC!
1! APP_11! TAAACAATAAAAAAAAAAATCTAAAACCAAA! GGATAAAAAYGTATTTTAGTAGTAGTTTTT!
1! APP_76! AAACATATTTTTAATTAAAAAAAACAATAA! ATTATAGAGTTTGTGGAAGAGGTG!
1! APP_12! GGTTTTAGATTTTTTTTTTTATTGTTTA! ACACCCRAAAAAAACCCCTAAC!
1! APP_91! ATAATATAATTCTCCAAAACCAAA! TGTTGTTTTATTTTATTTATTTAGTTTTT!
1! APP_15! GTTTGGTATTGTTTTTGTTGGT! TTCTCTACATTAAAAACTTAAATTAAAATCTTA!
1! APP_111! TTTAGTATGTATTAATATGAATTAATTAGAATG! AAACTCATAAAAAAAATCTATCTAACC!
1! APP_136! AGAATAATGTGGGAAGAAATAAATT! ACAAAACCCATTAATAATATAATATAAAAAC!
1! APP_141! TTTTGTTGGTTTTTAATTATTAAGAATTT! ATCTATAATCATCCTTCAAAAAAAA!
1! APP_146! TTAAAATGGAGTTGTTTTGGTTTAG! CCATTAAAAAAATACTATCAATATACCTCA!
1! APP_14! GGATTAGTTGATTYGTTTGGTTTTGAGTTT! ACCAACAAAAACAATACCAAAC!
1! APP_20! GGGATAGTTTAGGAAGTTAGGAGTT! CATACACAAAATTTACCTATAAAAAAC!
1! APP_110! TGTTTAGAGGGAAAATATTTTTGTATT! ACAATTCTCCTACCTCAACCTC!
1! APP_121! TGTTTAGTTGAGTTTGTTGATGT! TTTAATTTCTAAAATCACTTCAAATT!
1! APP_124! GTTGTTGTTGAAGAGGTTAATAAAAAT! TAAACTTATATAACACAAACCCCAAA!
1! APP_145! TTAATGGTTTGGGGATTAATTAATA! CATATTAACCACAACAAAATCTCC!
1! APP_1! TAGATAAGTGGTTGTTGGTTTTTTT! TCCTAATAACTTTTTACTTTTCAACC!
1! APP_2! GGATTTTTGAGTAGTGAAGGAATTA! TCTTAAATTTAACAATTTCTCTTTCC!
1! APP_4! TGATTTTAGGTGATTTGTTTATTTG! AAACCCAATTATTCACTTTCTACAC!
1! APP_6! TAGGATAGATATAATGAAGAATAAGGGTAG! AAACAAAAATATAACATCCATCTAAATTAA!
1! APP_10! GGATAAAAAYGTATTTTAGTAGTAGTTTTT! ATACAAAATCAAAAAAAAATAAATCCTAAAAC!
1! APP_13! GTTAGGGGTTTTTTTYGGGTGT! AAACTCAAAACCAAACRAATCAACTAATCC!
1! APP_19! TTTTTAAAGTTAGTTTTTYGTTTTTGAA! AACTCCTAACTTCCTAAACTATCCC!
1! APP_23! GTTTGGGAGGGGGTAGAGA! CCAAAAACTTTACAACCCAACACA!
1! APP_28! TTTGAAGATGTTTAGAAGTTGTTTGT! TTTTTCTTTTAAAAAATTACTAAAAAAC!
1! APP_45! GTTTATTATAAATTTAAGGTTATTTGGA! TTAATACAAAAATCTAACAAAAATACA!
1! APP_75! ATAGTGAAGATAAAGTAGTAGAAGTAGTAGAGG! AATAATAATAATAACAATACTAATAATTCTCTC!
1! APP_113! GTTATGGTAATGTTGTGGGTAAGTT! TCTCTAAAAAATAAATCACATACAAAAAA!
1! APP_117! TTTGGTTAATATGATTAGTGAATTAAGGAT! ATCAACCCCAAAAAAATACCAC!
1! APP_140! ATAATTAAAAACCAACAAAACACCC! ATTAGGTATTGAGATTTTAAGTTTTTT!
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1! APP_6.1! ACCAACCCATTTACTTCTTCTTAAAAAC! TTAATTTAGATGGATGTTATATTTTTGTTTAAT!
1! APP_18.1! TCCCCCCTATCTAAATATCTCTC! AGGGTAGGGGGYGATTTTGAG!
1! APP_5! TGAATAATTGGGTTTGTTTTGTTAT! AAATTACTTTTACCCCTAAATATCCTTTA!
1! APP_8! TTTGTTTTTAAGAAGAAGTAAATGG! ATTAAAACAACAAAACCTCATTTTT!
1! APP_9! AAAATGAGGTTTTGTTGTTTTAATAAG! AAAAACTACTACTAAAATACRTTTTTATCC!
1! APP_16! TAAGATTTTAATTTAAGTTTTTAATGTAGAGAA! ACTCCCTAARACAAAACTAAACC!
1! APP_17! GGTTTAGTTTTGTYTTAGGGAGT! ACTCAAAATCRCCCCCTACC!
1! APP_18.2! ATTCAAAAACRAAAAACTAACTTTAAAAAC! GAGAGATATTTAGATAGGGGGGA!
1! APP_21! TTTTTTATAGGTAAATTTTGTGTATGTT! ACCTTCTACCTCTCAAACAAAACT!
1! APP_22! AGTTTTGTTTGAGAGGTAGAAGGT! TCTCTACCCCCTCCCAAAC!
1! APP_24! TGTGTTGGGTTGTAAAGTTTTTGG! AAACTAAACCAAAATCCCCAA!
1! APP_32! TTGATTGTTTTTTATAGAGTTTAGAAA! AAATTTATTAAACTCACACCTCTATC!
1! APP_34! ATTTCCTCAATCAAAACCAATATTA! TAGTAAAGTTTAGGTTTGATGGTGATT!
1! APP_36! CTACTAAATTTAATACACTTCTCACTAATAATT! TTTTTGTATATTAGAGTTTTTTATAGATATTTG!
1! APP_81! TTGTTGGAGGGATTAAATTTAAGTG! CCTAAATAATCTTAAATAAACTTTAAAACAC!
1! APP_135! AATTTATTTCTTCCCACATTATTCT! TTTTTTGAGTAGATGTAGAATTAGATTTT!
1! APP_137! TTAATTAAATCACAAACCACAAAAATAATATAC! TTTGTGTATTGTAAAGAATTTAGTTGTATTAAA!
1! APP_25! GGGTTTTGTTTTGTGTATTTAAGGA! ACCCTCCCCAACATCCTATAC!
2! APP_26! GGTTTAGTTTTTTTGGGGGTATA! CCACACAACTTTTCTTTACTACACTAC!
2! APP_27! TGTGGAGGTTGTAGTTTAGTGAAA! ACAAACAACTTCTAAACATCTTCAAA!
2! APP_29! GTTTTTTAGTAATTTTTTAAAAGAAAAA! TCCTAAACCACTTATAAATAAAAATCAA!
2! APP_30! TTTTTTTTGATTTTTATTTATAAGTGGTT! ATCAAAATTCTCTTAATTAAATACATTTTT!
2! APP_31! GGGTGGAGGTGAGATTTATATTATGT! ACCTATTTTCTAAACTCTATAAAAAACAATCAA!
2! APP_33! TTTTTTTTGTTGAGGGTTTAATTTA! AATCACCATCAAACCTAAACTTTACTA!
2! APP_35! TAATATTGGTTTTGATTGAGGAAAT! ACAACAAAACTTAACATAAAAACAAC!
2! APP_37! AAAGTTTTTAGAATGTAAGGTTTAGTT! ATTCCACTTTATTTTATTATCATATACATATTT!
2! APP_38! GTGATGGAATAAAGTAATGATTTTTG! TTACTTTCAAAAAACAAACACAACA!
2! APP_39! TGAGGTTTTTAGAAAAGAGTTTGATAT! TCTATTTCAATAACACCAACAAACA!
2! APP_40! AAGAAAATTTTATAAAAGGAAATTGATT! AATCAACAACATATCAACACTAACC!
2! APP_41! GGTTAGTGTTGATATGTTGTTGATTTA! AACAACTATAAAATACTCCCTAAAA!
2! APP_42! TTTTGAAAAGAGTTAAAATTGTTATTAAAT! CCAAATTATCTCTAAAAAAAACAAACTA!
2! APP_43! TAGTTTGTTTTTTTTAGAGATAATTTGG! AACTATCCCTACAAAAATACCTACTATT!
2! APP_44! AATAGTAGGTATTTTTGTAGGGATAGTT! CTTTAAAAACTAATCATATTATCTCAACTTATA!
2! APP_46! TTTTAGTATTTTTGGTTAGTTAATTTGGT! CATTTTCCAAACAATAAACATATTC!
2! APP_47! TGTTTGGAAAATGTTTATTTGAATATA! CAAAACAACAAATACTAATAATTATCAAAC!
2! APP_48! TTATTAGTATTTGTTGTTTTGTTTAGTTATTAA! AAAACTAATTATCAAAAATTTCAATATAACC!
2! APP_49! TTAGGAAATTATGGATGTGATAGAAATA! CCTAAATTCAAACTATTCTCCTACCT!
2! APP_50! AAAATATTGAGATTATGTAAGAATTTGATT! CCATCTATTTTCTACATTTAAACCAC!
2! APP_51! GATGGTTTTTATTAGTTAGAAATTTTAAAATTA! AAAAAAAATAAACAAAAAACTCTCTATTTTACT!
2! APP_52! TTTTTTTTGTTTTTAAGATTTGTAGTATTT! ACTTTCCCATAAAAAAACAATATTC!
2! APP_53! ATGTTAGTGGTAAGTTATTTAGTTTATAAGAAT! AAATTAAAATTACTTTACAAAAATCTAAAACA!
2! APP_54! TTTAATTTAAAGGAGTGTTGAAGAT! TATCCATAACTCCAAAACAAAAACT!
2! APP_55! TTAAGTTTTTGTTTTGGAGTTATGG! CACTTCCCATTCTAAACATTCATATA!
2! APP_56! ATATGAATGTTTAGAATGGGAAGTG! TTTTAAAAACAAATACATATAATCCAAC!
2! APP_57! TTTAATTTTGAGTATGAAAGTGTGG! TTTCCAAATAATAACCTTATATAAAAACAA!
2! APP_58! AAGGTTATTATTTGGAAATATAGTATGTTG! CTAAAAATACAATCTCTAACTTAATTAAAAAAA!
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2! APP_59! GTTTAGGATATGTTTTGTTTTGGTT! CCTAAATTAATAATTACTCCAATTTATTTAAA!
2! APP_60! TATGTTTTTTAGGGTGGATTTTT! ACCACTAAAAATTTAATATTCCCATAAC!
2! APP_61! TGTGGTAGAAGTTAATTAATTAGTGATTATT! TTCTTCCCTCAAAACCAAAC!
2! APP_62! TAGTTTGAAGATGTTTGAAGTTTGA! ACACACCAAACAAAAAATAAATACAT!
2! APP_63! TTTTTGTATTTAAATAAATGTATTTATTTTTTG! TTCCTTTACTACTTTTCTACTTAACTAAATTTT!
2! APP_66! AAGTAGAGTTATTTTGGGAAGGTTT! AATTTTCAAACTCAAACCATACTTC!
2! APP_67! AATTTGTTTTGAAGTTTATTTTTTTT! CAAACATCCATCCTCTCCTAATATAA!
2! APP_68! TATATTAGGAGAGGATGGATGTTTG! AACTATTACCTCAAAATACCCCTAAA!
2! APP_69! TTTAGATTTTAGTTTTTAGAGTGATTTTAG! AATTCAACTAACCCTATTTTTAACTTTT!
2! APP_70! TTTTTTTTATATTTTGTAGATATGTAGTGAGA! ACAAAATCCACATTATCACTTTCTT!
2! APP_71! ATTGGTTGAAGAAAGTGATAATGT! CATCTCTAAAACTAAACACAAAAACC!
2! APP_72! GTTGTTTTTTTGTATTGTATTTTGAGA! CCACTCTTACTTAACTCATCCACTAA!
2! APP_73! GTTGTTATAATGTTGGGTTGGTAGT! AACCAATTCCCTCAAAAAAAA!
2! APP_74! GGGATTTATATTTAGATTTGTTGAATT! TTTATCTTCACTATAAAAACAAACACAA!
2! APP_77! AATAGATTGATTTTTTTGGTTTTTG! AAACACATCCATAACCATACTTTATC!
2! APP_78! TGTTTTTTTATGTTAAATGTGGTTTT! AACACACTTCCCTTCAATCAC!
2! APP_79! TGATTGAAGGGAAGTGTGTTT! AATCTATTACAAAAAACAAAATCAAT!
2! APP_80! TGATTGGATGATTGTAGTTTTTG! TCACTATAACAAAAAACCTTTATTCC!
2! APP_82! AAGTTTATTTAAGATTATTTAGGAATTTTTT! TATTCAAAAAACACAAAACCATACA!
2! APP_83! AGTTTTGAGATTTGAATAGGATGTATTA! CATTTAAATTTAAATCCCATTTCTTT!
3! APP_84! ATTTTAATGTTATAATTGTAAAATGGATTA! CAAAACAAAAAATTTAATAAAACAAC!
3! APP_85! AATTTTTTGTTTTGAGAAATAATTGAAAA! CATCAAAAATACTAACTACTATTATAAAAACT!
3! APP_86! TTTTTTTTATTTTATAGTTTTTATAATAGTAGT! CTTAACCTCAAACCTCTCTTTAACTT!
3! APP_87! TTAGAAAGTTAAAGAGAGGTTTGAG! TTAAAAATCTTAATAAAACCAACAAAC!
3! APP_88! AAAATGATAAAAATAGAGGAAAAATATAATTAT! CCTTCTTATCAACTTTAAACAAATTCT!
3! APP_89! AAGAAGGTAGTTATTTAGGTAAAATTTGA! AAATTCATAAAACTATAAACAATCACAC!
3! APP_90! TTTATGAAATATTGATTTTTAATGAGAAA! AAACAACAATTTCAAATCTTCTAAAA!
3! APP_92! GTTTGGTTTTGGAGAATTATATTAT! TACTCAAAACATTTCTCCTCATTCT!
3! APP_93! TTTGATGTTTAATGTTTTGTAGAAATG! CTCTACCTCCCAAATTCAAATAAT!
3! APP_94! GGTAGGATTATGTTTAGGGTTTTTAA! TTATCCCACTCCACAACTTTATACT!
3! APP_95! TTGTTTTTGAGGGATAGAGATAATTAT! CATTAATTTAACCACCTAAACACATC!
3! APP_96! GGTTTTTTTGAATTATTTGATGTTT! ACCTAAAAAACCCCTTCACTATTTA!
3! APP_97! AATGTTGAGTAAGGAGGATAGTTATTATATAT! AAATCACCTTTTTACAAATCTACCTT!
3! APP_98! AATGTTTAGAAGGTAGATTTGTAAAAAG! ATACAAAACACTACTTCTTCCATTAAC!
3! APP_99! GTGTTTTGTATAAATTTGAAAAAGAGTT! AAATACTTTAAAATATACTATCTATCCTTCTA!
3! APP_100! AGAAGGATAGATAGTATATTTTAAAGTATTT! TATCACCAACCCAAAAAACAA!
3! APP_101! TTGTTTTTTGGGTTGGTGATA! CCAAAAATTAAAAAACTCTTACCATAA!
3! APP_102! AGTGTTTGGTAAGAAAAATAATTTG! AACCTACATCAAAAAATAACAACTC!
3! APP_103! TGTTGATTTGGAGTTGTTATTTTTT! AAACAACTTACTTACCAACTTCATCCTA!
3! APP_104! TGGTAAGTAAGTTGTTTTTTTGATGTT! CTAATTCCAACCTAACAATTTCATC!
3! APP_105! AAATTGTTAGGTTGGAATTAGTTT! CCAAAACATCATAATTTAAAAACCATAA!
3! APP_106! AAAATGAAAATTTTTAGATTATTGGAG! ACCTATATCACAACTAAATTTACTAAAATCA!
3! APP_107! TTTTTTTGGTATTAGAGGTGGTG! TTAAATCATTTCCTCTCCAATAAAC!
3! APP_108! AAGGGTATTGGAAGAGGAATAGAGT! CCTTTACTCAAAACTAAAATTAAACAAAAA!
3! APP_112! AGATTTTTTTTATGAGTTTGAGAGA! CCACAACATTACCATAACAACTATAC!
3! APP_114! TTGTGGATTGATTTTTAGAAAATTT! TCCTCAAATATTAATTTTCATACTCTTAC!
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3! APP_115! TTTTTATATTTGTAAAAGGGAGATGATA! AAATAACAACAATCACAACAACAAC!
3! APP_116! GTTGTTGTTGTGATTGTTGTTATTT! ATCCTTAATTCACTAATCATATTAACCAAA!
3! APP_118! TATTTTTTTGGGGTTGATTTTG! AAACATACAAAAAATAACTCTCTCTCTTAC!
3! APP_119! GGTTTTTATTAGAAAATTAAGGAGTAG! AACATATACAATAAACAAATTACAAAAA!
3! APP_120! TTTTTGTAATTTGTTTATTGTATATGTT! CATCAACAAACTCAACTAAACAC!
3! APP_122! ATGAGTAAAATTAATTGGTTGTTTT! CCAATTTTTAATAATAAACTTCATATC!
3! APP_123! GGATATGAAGTTTATTATTAAAAATTGGTA! TAAACAAACATTATATTTTTATCTTTTCCT!
3! APP_125! TGGGGTTTGTGTTATATAAGTTTATTT! CCTTTAAAAAAATACTATAATTTTATAATATTC!
3! APP_126! TGTATTTAAGAAATGAAATTTTTTTAATT! ATTACACCTTTATTTAAACCCACA!
3! APP_127! TGGGTTTAAATAAAGGTGTAATTATT! AATTCCCACTTAAAAACATACAATC!
3! APP_128! GTGGAGGTAGGTAAATTTGATTGTA! AAAAAACAACTATAACCCAAACATC!
3! APP_129! AATTATTTGAATTTGGGAGGTAGA! ATATACAACTCCCTCATCCCTTAA!
3! APP_130! TTTAAGGGATGAGGGAGTTGTA! TCAATATAATCAAATCCCCTATAATC!
3! APP_131! GGGATTATAGGGGATTTGATTATAT! CCAACTACTCCAAAAACTAAAACA!
3! APP_132! TTGGGTTTATTTATTTATTGTGGAG! CCCACCAATTACACAAATACTATACT!
3! APP_133! TAGTATTTGTGTAATTGGTGGGTAA! AAAATAAAAATCAATCTTTTAAAAATAAA!
3! APP_134! GTATTTTTTATTTTTTTATTGTTTTTTTAT! TACTCAAAAAACTTATAAATTAAATTTTC!
3! APP_138! TTTTGTGGTTTGTGATTTAATTAAGT! AAACATCTAAAATACTTAAAAATATTTAACTTT!
3! APP_139! AAAGTTAAATATTTTTAAGTATTTTAGATGTTT! AAAAAACTTAAAATCTCAATACCTAAT!
3! APP_142! TTTTTTTTGAAGGATGATTATAGAT! TTTATCCAAACATACCTTCCTCATC!
3! APP_143! GGTAGATTTAATTTTTTTTAATTAGTTTG! AATAATACTCCTCCAAAAATATATTTATTT!
3! APP_144! AAATAAATATATTTTTGGAGGAGTATTATT! CTCAAACTTACAATTAAAACACAACA!
!
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